FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
NCT06695117, the first vaccine candidate, combines SNY's influenza protein-based trivalent vaccine, Fluzone High-Dose and Novavax 's NVAX adjuvanted recombinant Novavax COVID-19 vaccine, NVXC19. NCT06695130, the second vaccine candidate, combines SNY's influenza recombinant protein-based trivalent vaccine, Flublok with NVXC19. SNY markets Fluzone High-Dose and Flublok flu vaccines. Novavax recently signed a multi-billion dollar deal with Sanofi for its protein-based COVID-19 vaccine. Per the deal, from 2025 onwards, Sanofi will gain rights to co-market Novavax's COVID-19 vaccine globally, except in certain countries where the company has existing partnership agreements. The French drugmaker also has the sole license to develop and market the Novavax vaccine in combination with its influenza vaccine. Year to date, shares of Sanofi have lost 3.3% against the industry's growth of 8.9%. Image Source: Zacks Investment Research Per the company, NCT06695117 and NCT06695130 are
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million MilestonePR Newswire
- Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3% [Yahoo! Finance]Yahoo! Finance
- NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines [Yahoo! Finance]Yahoo! Finance
- Novavax, Inc. (NASDAQ: NVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
NVAX
Earnings
- 11/12/24 - Beat
NVAX
Sec Filings
- 1/3/25 - Form 4
- 1/2/25 - Form 4
- 1/2/25 - Form 4
- NVAX's page on the SEC website